The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.

Kalindi ParmarBose S KochupurakkalJean-Bernard LazaroZhigang C WangSangeetha PalakurthiPaul T KirschmeierChunyu YangLarissa A SambelAnniina FarkkilaElizaveta ReznichenkoHunter D ReavisConnor E DunnLee ZouKhanh T DoPanagiotis A KonstantinopoulosUrsula A MatulonisJoyce F LiuAlan D D'AndreaGeoffrey I Shapiro

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Prexasertib exhibits monotherapy activity in PARP inhibitor-resistant HGSOC PDX and cell line models, reverses restored HR and replication fork stability, and synergizes with PARP inhibition.

Keyphrases

high grade
dna damage
dna repair
low grade
combination therapy
open label
dna damage response
clinical trial
oxidative stress